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Endovascular Thrombectomy in Patients with Large Core Ischemic Stroke: A Cost-
Effectiveness Analysis from the SELECT Study 
 
Abstract: 
Background: Whether endovascular thrombectomy (EVT) is cost-effective in large ischemic 
core infarcts is unknown. 
Methods: In the prospective multicenter cohort study of imaging selection study (SELECT), 
large core was defined as CT ASPECTS < 6 or CTP ischemic core volume (rCBF<30%) ≥ 50 cc. 
A Markov model estimated costs, quality-adjusted life years (QALYs) and the incremental cost-
effectiveness ratio (ICER) of EVT compared to medical management (MM) over life time. The 
lower and upper willingness to pay (WTP) per QALY were set at $50,000 and $100,000 and the 
net monetary benefit (NMB) for EVT were calculated. Probabilistic sensitivity analysis (PSA) 
and cost-effectiveness acceptability curves (CEAC) were assessed for EVT in SELECT and 
other pivotal EVT trials. 
Results: From a prospective cohort trial of 361 patients, 105 had large core on CT or CTP (EVT 
62, MM 43). 19 (31%) EVT patients achieved mRS 0-2 vs 6 (14%) MM patients (aOR: 3.27, 
95% CI: 1.11-9.62; P = .03) with a shift towards better mRS (adj cOR: 2.12, 95% CI: 1.05-4.31, 
P = .04). Over the projected lifetime of stroke patients presenting with large ischemic core, EVT 
was associated with incremental costs of $33,094 and a gain of 1.34 QALYs per patient, 
resulting in ICER of $24,665 per QALY. EVT has a higher NMB compared to MM at the lower 
(EVT: -$42,747 vs MM: -$76,740) and upper (EVT: $155,041 vs MM: $57,134) thresholds of 
willingness to pay. The PSA confirmed the results and the CEAC showed 77% and 92% cost-
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effectiveness probability of EVT at the WTP of $100,000, respectively. EVT was associated with 
an increment of $28,962 in societal costs. The Pivotal EVT trials (HERMES, DAWN and 
DEFUSE 3) were dominant in a sensitivity analysis at the same inputs, with societal cost savings 
of $38,072, $86,358 and $22,837, respectively. 
Conclusion: EVT may result in better outcomes in large core patients with higher QALYs, 
NMB and high cost-effectiveness acceptability rates based on current WTP thresholds.  




Introduction   
Stroke is a global health problem, with more than 13 million new strokes and 5.5 million deaths 
every year1. In the USA, every year 795,000 individuals suffer from new or recurrent stroke, 
resulting in 140,000 deaths2. Stroke is also the leading cause of serious long-term disability, 
resulting in 116.5 million quality-adjusted life year (QALY) lost1 worldwide every year. 
Moreover, it is an expensive disease to treat and manage with annual direct costs of $28 billion 
and indirect costs of $17.5 billion on the US economy, with a projected increase in direct costs to 
$94.3 billion by year 20352. Effective stroke treatments that improve clinical outcomes and 
reduce disability may help reduce the economic burden of stroke in society and in our health care 
systems by reducing direct and indirect costs.   
 
Endovascular thrombectomy (EVT) has been established as a transformative treatment for 
ischemic stroke patients with large vessel occlusion; safety and efficacy have been well 
documented in patients with small ischemic core infarcts, both in early3–7 and late8,9  time 
windows. While randomized trials for efficacy and safety of EVT in patients with large ischemic 
stroke are ongoing10–13, potential evidence of EVT efficacy and safety in these patients was 
recently presented from a large, multicenter, prospective cohort data14. With prevalence of large 
core strokes estimated to be as high as ~30%14, these patients are frequently encountered in daily 
practice. Treating physicians have several considerations while determining the treatment 
approaches, such as the poor natural history in patients treated with medical management only as 
compared to the lower likelihood of functional independence and the potential safety concerns 
with EVT. One of the considerations for the healthcare systems and for society is whether 
treatment with endovascular thrombectomy is cost-effective. While cost-effectiveness of EVT in 
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patients with small ischemic core has been assessed and deemed favorable15–21, it remains 
unknown whether EVT is cost-effective in patients presenting with large ischemic core infarcts. 
The implications of EVT on societal costs related to large stroke patients have also not been 
studied in detail. 
 
We sought to assess EVT cost-effectiveness by performing a cost- effectiveness analysis for 
EVT as compared to medical management only (MM) using outcomes in patients with large 
ischemic core infarcts on CT (ASPECTS <6), CTP (rCBF <30% volume ≥ 50 cm3) or both from 
the SELECT study, a prospective, multicenter cohort study of imaging selection22.  
This study sub-analysis aims were: 
1. To assess the overall gain in QALYs 
2. To identify the incremental cost-effectiveness ratio (ICER) for EVT 
3. To assess the net monetary benefit (NMB) at various thresholds of willingness to pay 
(WTP) 
4. To compare EVT cost-effectiveness in patients with large ischemic core to those with 
small core infarcts. 




“The Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke 
(SELECT): a Prospective Multicenter Cohort Study of Imaging Selection”22 enrolled patients 
with stroke attributable to large-vessel occlusion who were treated with endovascular 
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thrombectomy plus medical management or medical management alone, based on CT or CTP 
findings, up to 24 hours from the point that they were last known to be well at 9 comprehensive 
stroke centers across the United States. The decision to proceed with EVT vs medical 
management alone was made at the discretion of the local investigators in a nonrandomized 
fashion. The study initially included patients up to 8 hours after stroke onset, with the enrollment 
window extended up to 24 hours after the results of the Clinical Mismatch in the Triage of Wake 
Up and Late Presenting Strokes Undergoing Neurointervention With Trevo (DAWN) trial8 were 
announced. Patients with large ischemic cores were defined as having an ASPECTS of 5 or less 
on non-contrast CT or an ischemic core volume of 50 cm3 or more on CTP based on the volume 
of tissue with a relative cerebral blood flow less than 30% at presentation. 
Cost-Effectiveness Analysis: 
We performed a cost-effectiveness analysis to compare costs and outcomes of endovascular 
thrombectomy (EVT) in addition to medical management (MM) compared to MM only in 
patients with large core acute ischemic stroke. The outcome measures were quality-adjusted life 
years (QALYs). QALYs are assessed using the survival time and the utility associated to the 
modified Rankin Scale (mRS) score. For each mRS score we used utility values obtained from a 
recent consensus analysis. The analysis took the health care service provider perspective, 
including only the costs of direct medical treatment (hospital admissions, ICU, rehabilitation). 
An analysis from societal perspective was also attempted that accounts for the societal costs (as 
in productivity losses, informal care and private cost for patients). Costs were calculated in 2017 
US$, inflated where necessary23. The time horizon was selected to be over lifetime. All costs and 




We created a decision analysis model to assess cost-effectiveness of EVT using TreeAge 
Healthcare Pro version 2020 (TreeAge, Williamstown/MA). The treatment arms include best 
MM (including the use of IV tPA where applicable) without subsequent EVT vs best MM 
followed by EVT. The decision model consisted of two different models 1) a short run model to 
assess the transitions measured at 90 days following stroke and 2) a long run model to assess 
transitions over the course of lifetime following the initial stroke, beginning at 90-day post 
stroke. The short run model analyzed the clinical outcomes and costs associated with the 
treatment at 90-day interval following the index stroke. The long run model was created to 
estimate the transitions in clinical outcomes and associated post-stroke costs with cycles of 1 
year. At the end of each cycle, the patient could remain in the same health state, experience a 
recurrent stroke and recover to the same state or transition to other states or die from stroke or 
other causes. Outcomes were based on modified Rankin Scale (mRS) scores measured at 90 days 
after stroke.24  
 
Model Input Parameters 
The initial probabilities for short run model to analyze 90 day clinical outcomes were identified 
from the large core cohort of the SELECT study14. The study reported outcomes of 105 patients 
(62 EVT, 43 MM) with large ischemic stroke on non-contrast CT, CT perfusion or both; 
demonstrating functional independence rates of 31% and 14% in patients treated with EVT and 
MM respectively. For comparative models for patients with small core, results provided in 
HERMES metanalysis25 were used for short run models in early time window (0-6 hours), 
DAWN8 and DEFUSE 39 results were used for trials beyond 6 hours of stroke onset. The 
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transitional probabilities beyond 90 days of stroke onset were populated using historical data 
from multiple prospective cohort studies, identifying probabilities of recurrent stroke, death and 
changes in functional status over the course of time for patients suffering from index stroke.26–28 
The measures for utilities at different mRS categories were obtained from a prospectively 
validated cohort evaluating EuroQol in post-stroke patients.29 Table 1 provides further 
information regarding the parameters used in the decision analysis model. 
Treatment Costs 
Data was used from the National Inpatient Sample30 and data available in the literature31 to 
estimate costs and we inflated as necessary using the inflation rate from national sources24. The 
costs are presented in Table 1.  
The additional cost of IV thrombolysis was estimated to be $6,961, including the cost of the 
therapy, the medication and administration from the National Inpatient Sample30, inflated at the 
2017 US $.    
The cost of the EVT varied in each trial was estimated to be $14,454. This includes the cost of 
the devices (stent-retreivers), materials and intervention.  
The health care costs in the 3 months following a stroke include the acute management (length of 
stay in the acute stroke unit, in the acute high dependency unit, and in the rehabilitation ward, as 
well as the supported discharge cost and community care costs) and rehabilitation costs.32 The 
ongoing costs in the following years include rehabilitation costs and follow-up costs.31 Both 
acute and ongoing costs were applied based on the disability observed at 90-day on modified 
Rankin Scale score in 7 different categories. The cost of a recurrent stroke was estimated as the 
mean expected cost to treat an average stroke that does not need MM or EVT.33 
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Initial and Transitional Probabilities 
The initial probabilities were defined based on modified Rankin Scale score at 90 days and were 
assessed using results from the SELECT study for patients presenting with large ischemic core 
for the main results. The initial probabilities for comparison models with the trials were assessed 
from the results published from the DAWN8 and DEFUSE 3 trials9 and HERMES meta-
analysis25. The transitional probabilities were defined as the probability to move from one health 
state to another after 90 days results and were implemented in annual cycle for the long run 
model for a horizon of lifetime. The age specific annual death rates were obtained from United 
States Life Tables.27 Excess deaths because of stroke were incorporated as additional hazard 
ratios identified from the contemporary cohort studies.28 The other transitional probabilities were 
also obtained from various large prospective cohorts.26   
Cost-Utility Measures and Outcomes: 
The cost-effectiveness of EVT was expressed in terms of its incremental cost-effectiveness ratio 
(ICER), defined as the ratio of the difference in the costs between EVT and MM and gain in 
Qality Adjusted Life Years between the treatments demonstrated by the model. 
𝐼𝐶𝐸𝑅 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐸𝑉𝑇 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑀𝑀
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝐸𝑉𝑇 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝑀𝑀
 
Results are also expressed in terms of net monetary benefits (NMB), calculated as the mean 
QALYs per patient accruing to that treatment multiplied by the willingness to pay (WTP) for a 
QALY (the cost-effectiveness threshold) minus the mean cost per patient for the treatment. 
10 
 
𝑁𝑒𝑡 𝑀𝑜𝑛𝑒𝑡𝑎𝑟𝑦 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 = [𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑤𝑖𝑡ℎ 𝐸𝑉𝑇 𝑋 𝑊𝑖𝑙𝑙𝑖𝑛𝑔𝑛𝑒𝑠𝑠 𝑡𝑜 𝑃𝑎𝑦] −
 𝑀𝑒𝑎𝑛 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐸𝑉𝑇   
 
The lower and upper willingness to pay for NMB calculations were set to $50,000 and $100,000 
per QALY.  
Analysis from Societal Perspective: 
To assess the impact of index stroke on overall societal productivity, we used human captial 
approach to calculate costs associated with lost productivity as well as costs of informal care 
provided by the family. Lost societal productivity due to premature deaths and post stroke 
morbidity were calculated separately. Using US Census Bureau34 gross wages and age-based 
employment rates provided by US Bureau of Labor Statistics35, lost productivity due to 
premature mortality was calculated. Furthermore, we assumed complete retirement at age 80. 
Non-stroke related premature deaths were not considered for these evaluations.  
To obtain the lost productivity due to stroke-related morbidity, the aforementioned productivity 
measures were multiplied by relative earnings of stroke survivors (82.5%) and probabilities of 
return to work (RTW) based on 90-day functional status. The cost of informal care provided by 
the family members were stratified based on 90-day functional status and calculated using hourly 
wages for home health aides for year 2017.34  
Sensitivity Analysis 
A probabilistic sensitivity analysis (PSA) was performed to establish the impact of the 
uncertainty characterising the input parameters and assess the robustness of the results, using 
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10,000 runs for the second order Monte Carlo simulation. A distribution was assigned to each 
parameter value and a random value from the corresponding distribution was selected to be used 
as an input for the Markov model. The mean (median) cost, QALYs and NMB for each treatment 
were calculated from the 10,000 simulations; and the probability that the interventions are cost-
effective is summarised in the cost-effectiveness acceptability curves (CEACs). We also 
conducted the same analysis, using the data from randomized trials that proved EVT efficacy and 
safety in patients with small ischemic core: HERMES25, DEFUSE 39 and DAWN8. 
 
Results 
Functional Outcomes in Patients with Large Ischemic Core Infarcts: 
Of 361 patients enrolled in SELECT, 105 (29%) had a large ischemic core on CT or CTP or both 
(EVT 62, MM 43). Functional independence (modified Rankin Scale score of 0-2) at 90 days 
was achieved in 19 (31%) EVT patients vs 6 (14%) MM (OR: 3.27, 95% CI: 1.11-9.62; P = .03) 
with a shift towards better mRS (cOR: 2.12, 95% CI: 1.05-4.31, P = .04)14. Mortality was 
observed in 29% (18/62) of EVT and 42% (18/43) of MM patients, p=0.17. Neurological 
worsening (EVT: 13/62 (21%) vs MM: 8/43 (20%), p=0.87) and symptomatic ICH (EVT: 8/62 
(13%) vs 3/43 (7%), p=0.51). 
 
Base Case Analysis: 
Using base case values, EVT following MM performed in patients with large ischemic core 
infarcts was associated with an incremental cost of $33,094 per patient over projected 
lifetime(Table 2).  EVT-treated patients could gain 1.34 incremental QALYs.  
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The ICER of EVT compared to MM was $24,665 per QALY. The EVT has a higher NMB 
compared to MM alone at the lower (EVT: -$42,747 vs MM: -$76,740) and upper (EVT: 
$155,041 vs MM: $57,134) thresholds of WTP, indicating that EVT is cost-effective. EVT was 
also associated with incremental costs of $28,962 in an analysis from the societal perspective.  
 
Sensitivity Analysis: 
Figure 2 demonstrates the probabilistic sensitivity analysis based on 10,000 simulations. A 
significantly higher proportion of results are in the quadrant where an increment in costs is 
associated with a QALY gain and most of the result are under the $100,000/QALY threshold 
line, therefore there is a high probability that EVT is cost-effective. The cost-effectiveness 
acceptability curves (CEAC) demonstrates the probability that each treatment is cost-effective at 
different values of the willingness to pay for a QALY (Figure 3). EVT has 77% & 92% 
probability of being cost-effective compared to MM when the willigness to pay is $50,000 and  $ 
100,000 per QALY, respectively. 
 
Comparison of EVT Cost-Effectiveness in Large Core Infarcts to Patients with Small Core 
Infarcts: 
Overall, data from HERMES meta-analysis in early time window and DAWN and DEFUSE 3 in 
late time window demonstrated overall higher lifetime costs associated with MM as compared to 
EVT. Cost-effectiveness analysis based on data from HERMES meta-analysis demonstrated 
average overall cost savings of $29,964 over lifetime in patients treated with EVT, with a gain of 
1.62 QALY (i.e. dominant over MM) and almost 100% probability of EVT being cost-effective 
in probabilistic sensitivity analysis at lower and upper thresholds of WTP. EVT also decreased 
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the societal costs by $38,072. Similar results are obtained based on outcomes from DAWN trial 
(dominant) and DEFUSE 3 trial (dominant) with both the trials demonstrating almost 100% of 
being cost-effective at the willingness to pay thresholds of $50,000 and $100,000. EVT was also 
associated with a reduction in societal costs by $86,358 in DAWN and $22,837 in DEFUSE 3 
trial. Table 3 demonstrates the comparison of incremental EVT costs, QALYs, ICER and societal 
cost benefits in SELECT large ischemic core patients as compared to previously published RCTs 
over the horizon of lifetime.   
 
Discussion: 
We found that EVT may result in more lives saved and improved quality of life in large core 
patients from the SELECT prospective cohort study. This treatment strategy had an acceptable 
ICER, a higher NMB and high probabilities of being cost-effective at even the lowest bounds of 
current willingness-to-pay thresholds for the United States healthcare system.  
Our analysis suggests that in patients with large ischemic core on CT or CTP, EVT was 
associated with 1.34 QALY gained and ICER of $24,665 for each QALY gained. While it 
resulted in initial $33,094 incremental cost per patient, EVT was associated with more lives 
saved and improved likelihood of being functionally independent (mRS 0-2), increasing the 
QALYs.  
 
Our results showed an incremental lifetime cost associated with EVT as compared to prior RCTs 
that enrolled patients with small core.8,9,25 This is to a large part likely due to the high mortality 
rate in SELECT large core subpopulation that received MM only; 42% as compared to 19% in 
HERMES25, in 26% in DEFUSE 39 and 18% in DAWN8. Such a high mortality rate 
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paradoxically largely reduces the cost in the MM group. For example, healthcare policy makers 
recognize that life-saving interventions may increase long-term expenditures, creating counter-
intuitive results. Prominent examples include the effect of smoking cessation or of several 
preventive measures, which may increase costs in the long run due to a higher life expectancy of 
the population.36,37  
Within the same lines, the social cost was higher in our large group cohort due to the reduced 
mortality with EVT primarily with similar rates of severe and profound disability (mRS) 4-5 
between EVT and MM as compared to a difference within the same mRS grades in prior EVT 
RCTs. Additionally, the median age for our cohort was higher than prior RCTs which may have 
resulted in an underestimation of the potential savings attributable to EVT and overall savings 
including productivity losses and higher societal costs.  
Previous studies demonstrated the cost-effectiveness of EVT compared to MM up to 24 hours of 
stroke in small core infarcts15–21 with ICER significantly below the current willingness to pay 
thresholds in patients included in randomized controlled trials (put references only from RCTs). 
Since most of these trials excluded patients with large ischemic core, involvement of these 
patients in such analyses is limited. Prior report18 demonstrated cost-effectiveness of EVT in 
patients with ASPECTS of 0-5 at a higher ICER, however concluded that the estimates may be 
uncertain because of systemic exclusion of such patients from the trials. 
With several ongoing clinical trials assessing the efficacy and safety of EVT in stroke patients 
with large ischemic core on different imaging modalities (SELECT 213, IN EXTREMIS12, 
TESLA11, TENSION10), the randomized evidence is forthcoming in this important sub 
population, which represents more than 20% of the patients encountered in daily practice. 
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Meanwhile, our cost-effectiveness analysis from the SELECT prospective cohort14 suggests that 
EVT may be cost-effective. These results, while still need to be confirmed based on data from 
the upcoming RCTs, represent further evidence from economical, societal and quality of life 
assessment to justify these randomized trials to evaluate intervening in patients with more 
extensive areas of infarct.   
There are limitations to our study that should be considered when interpreting the findings. This 
includes the lack of randomization and potential selection biases associated with prospective, 
cohort data. Additionally, we did not have direct economic data from the prospective cohort and 
thus relied upon the overall payments based on current diagnosis-related group (DRG) for EVT. 
Another limitation is represented by the variability in the methodology adopted in the different 
trials of EVT effectiveness in patients with small core infarcts, including the use of different 
devices and medical treatment to treat stroke. However, we conducted an extensive sensitivity 
analysis that confirms the results. 
The strengths of the presented study include data from a multicentre, prospective cohort study, 
use of prior validated methods, inclusion of probabilistic sensitivity analysis and comparative 
analysis with prior RCTs using the same parameters that allows for the direct comparison of 
cost-effectiveness.  
Conclusion: 
EVT may result in better outcomes and more lives saved in large core patients with higher 
QALYs, NMB and an acceptable ICER. This further justifies a randomized trial for EVT 
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Model Input Base-case value Distribution Source 
Initial probabilities for 
achieving mRS 0/1/2/3/4/5/6    
SELECT Large Core  Dirichlet Sarraj et al. 
EVT 0.0806/0.0645/0.1613/0.0968/0.2419/0.0645/0.2903   
MM Only 0.0233/0.0233/0.0930/0.1628/0.1628/0.1163/0.4186   
HERMES  Dirichlet Goyal et al. 
EVT 0.1000/0.1690/0.1910/0.1690/0.1560/0.0620/0.1530   
MM Only 0.0500/0.0790/0.1360/0.1640/0.2470/0.1350/0.1890   
DAWN  Dirichlet Nogueira et al. 
EVT 0.0900/0.2200/0.1700/0.1300/0.1300/0.0900/0.1600   
MM Only 0.0400/0.0500/0.0400/0.1800/0.1600/0.1800/0.1800   
DEFUSE 3  Dirichlet Albers et al. 
EVT 0.1000/0.1600/0.1800/0.1500/0.1800/0.0800/0.1400   
MM Only 0.0800/0.0400/0.0400/0.1600/0.2700/0.1600/0.2600   
    
Transition probabilities    
Recurrent stroke rate 0.059 (for 1st y) Beta Pennlert et al. 
Annual death rate 0.013 (for 65 y) Beta Arias et al. 
Annual death hazard rates 
for survivors mRS 
0/1/2/3/4/5 1.53/1.52/2.17/3.18/4.55/6.55 Log normal Hong et al 
After recurrent stroke control arm from HERMES meta-analysis Dirichlet Goyal et al. 
    
Health care costs    
Costs within first 90 days 
after stroke for mRS 
0/1/2/3/4/5/6 (excluding IVT 
and EVT) $7.996/$11.038/$17.336/$21.440/$28.729/$34,319/$8,067 Gamma Dawson et al. 
Additional cost of IVT 
treatment $6,961  Gamma NIS 2014 
Additional cost of EVT 
treatment $14,454  Gamma Shireman et al. 
Long-term annual costs 
after stroke for mRS 
0/1/2/3/4/5 $11,245/$11,579/$13,395/$23,009/ $46,553/$68,441 Gamma Shireman et al. 
Recurrent stroke 
hospitalization $23,032  Gamma Chambers et al. 
    
Utilities    
mRS 0/1/2/3/4/5/6 1.00/0.91/0.76/0.65/0.33/0.00/0.00 Beta 
Chaisinanunkul 
et al. 
    
Societal costs    
Paid workforce 
productivity    
Average annual earnings 






rate 0.312 (for 65 y) Beta 
US Bureau of 
Labor Statistics 
2017 
Relative earnings of stroke 
survivors 0.825 Beta Vyas et al. 
Return-to-work after stroke 
mRS 0/1/2/3/4/5 0.63/0.72/0.49/0.19/0.14/0.00 Beta Tanaka et al. 
Unpaid domestic productivity    
Informal annual caregiving 




Table 1 represents the model parameters and range of values used for sensitivity analysis. short 
term transition probabilities were used from SELECT14, HERMES, DAWN8 and DEFUSE 39 population. 
Long term transition probabilities were based on multiple large prospective cohort studies25, 27-29. Acute 
costs in the first 3 months include baseline medical management including adminstration of IV tPA. 







Thrombectomy Medical Management Difference 
Cumulative Lifetime 
Costs $207,866 $ 240,959 $ 33,094 
Cumulative Lifetime 
QALYs gained 3.96 2.62 1.34 
Incremental Cost per 
QALY gained   $ 24,665 
Table 2 demonstrates the Costs, QALYs, ICER and NMB of EVT versus Medical 
treatment (MM) Based on results from patients with large core in SELECT trial. All costs 






SELECT Large Core HERMES DAWN DEFUSE 3 
Incremental Costs $33,094 -$29,964 -$69,887 -$12,723 
Incremental QALYs 1.34 1.62 2.36 2.21 
ICER $24,665 Dominant Dominant Dominant 
Societal Costs $28,962 -$38,072 -$86,358 -$22,837 
 
Table 3 describes the incremental costs, incremental QALY and ICERs of EVT versus MM 
in USD in SELECT patients with large ischemic core over horizon of lifetime, as compared 
to the previously published RCTs of patients with small core infarcts in both early and late 
time window.  
The high cost of EVT was in part owing to the high mortality in MM patients in SELECT 
Large Core cohort, as compared to HERMES, DAWN and DEFUSE 3 cohorts. Similarly, 
the social cost of EVT in SELECT large core cohort was due to the reduced mortality with 
EVT primarily with similar rates of severe and profound disability (mRS) 4-5 between 






Figure 1. Decision model. A Short run analytical model is used to estimate costs within first 
3 months of stroke. A long run Markov model is used to estimate transitions between states 






Figure 2. Results of the Probabilistic Sensitivity Analysis (PSA). The figure demonstrates 
10000 simulated iterations of the incremental cost per QALY gained of EVT in patients 
with large core in the SELECT study (yellow), DAWN8 (green), DEFUSE39 (red) and 
HERMES25 (blue). The results show that the higher proportion of results are in the quadrant 
where an increment in costs is associated with a QALY gain and most of the result are under 
the $50000/QALY threshold line, therefore there is a high probability that the EVT is cost-
effective. The long dashed line represents an ICER of $50,000/QALY gained and short dashed 
line represents an ICER of $100,000/QALY gained. The high cost of EVT was in part owing 
to the high mortality in MM patients in SELECT Large Core cohort, as compared to 




Figure 3. Cost-Effectiveness Acceptability Curves (CEAC) of EVT versus MM in the data 
from large core patients in SELECT trial14 (yellow), HERMES25 trial (blue), DAWN8 trial 
(green)and DEFUSE 39 trial (red). The CEAC show the probability that each option is cost-
effective at different values of the willingness to pay for a QALY. Using SELECT data EVT has 
77% probability of being cost-effective compared to MM when the willigness to pay is $50000 
per QALY, and 92% probability of being cost-effective when the WTP is $100000 per QALY. 
Conversly, MM has 23% and 8% probability of being cost-effective when the WTP is $50000 
and $100000 per QALY respectively. EVT has a probability of being cost-effective of almost 
100% in all other trials with a WTP of $50,000 and $100,000 per QALY. The high cost of EVT 
29 
 
was in part owing to the high mortality in MM patients in SELECT Large Core cohort, as 
compared to HERMES, DAWN and DEFUSE 3 cohorts.  
 
